Abstract
Acute respiratory distress syndrome (ARDS) remains a significant source of mortality in critically ill patients. Characterised by acute, widespread alveolar inflammation and pulmonary oedema, its pathophysiological heterogeneity has meant that targeted treatments have remained elusive. Metabolomic analysis has made initial steps in characterising the underlying metabolic derangements of ARDS as an indicator of phenotypical class and has identified mitochondrial dysfunction as a potential therapeutic target. Mesenchymal stem cells and their derived extracellular vesicles have shown significant promise as potential therapies in delivering mitochondria in order to redivert metabolism onto physiological pathways.
Abstract
ARDS' biological heterogeneity is an obstacle in clinical translation of interventions. Analysis of metabolic alterations can inform development of therapeutics aimed at ARDS subpopulations. Mitochondrial dysfunction may be a potential therapeutic target. https://bit.ly/2XHfAFV
Footnotes
Provenance: Commissioned article, peer reviewed
Conflict of interest: M.J. Robinson has nothing to disclose.
Conflict of interest: A.D. Krasnodembskaya reports grants from the UK Medical Research Council, during the conduct of the study.
Support statement: A.D. Kransnodembskaya is supported by UK Medical Research Council Research awards (MRC MR/R025096/1 and MR/S009426/1). Funding information for this article has been deposited with the Crossref Funder Registry.
- Received April 22, 2020.
- Accepted June 4, 2020.
- Copyright ©ERS 2020.
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.